Acasti gets regulatory pathway for drug, names new CEO; shares rise

Grace Therapeutics

04/04/2023 15:57

** Drugmaker Acasti Pharma's shares  ACST.O  up 5.1% at 50 cents
    ** Co says the U.S. FDA will allow Acasti to proceed with a late-stage safety clinical trial
for its drug, GTX-104, subject to submission of the final clinical protocol 
        ** The drug is being developed for IV infusion in patients with aneurysmal Subarachnoid
Hemorrhage (aSAH), or bleeding over the surface of the brain triggered by a ruptured aneurysm
  
        ** Co also announces appointment of Prashant Kohli as CEO, succeeding Jan D'Alvise
    ** Kohli was co's Chief Commercial Officer since 2022 
    ** ACST fell 3.47% YTD 

 (Reporting By Akshita Toshniwal)
 ((Akshita.Toshniwal@thomsonreuters.com))